A formulation manufacturing facility of Aurobindo Pharma subsidiary near Hyderabad has been issued a warning letter by the U.S. Food and Drug Administration (U.S. FDA).
The company remains committed to working closely with the U.S. Subsequent to OAI, the unit has received a warning letter, Aurobindo Pharma said on Firday (August 14, 2026) even as the parent company shares were in the spotlight. Around noon, the shares on BSE were around 1.25% down at ₹1,636.20 each recovering from a sharper decline when the market opened. The said facility, Unit I of Eugia Pharma Specialities, is contributing to around 2% to the company’s overall group revenue, it said. On August 13, Aurobindo Pharma announced the incorporation of a new wholly owned subsidiary company Auropharm Overseas in India.
Aurobindo Pharma, in a filing, said it did not anticipate any impact on the existing supplies to the U.S. markets. FDA and continues to enhance its compliance on an ongoing basis, Aurobindo Pharma said. The new entity had been set up with the objective of undertaking manufacturing and marketing operations in India and foreign countries, it said in a filing.
